Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coegin PharmaNGM:COEGIN +0.60%29 PS Ratio is 223.33 as of Jul. 14, 2026, which is 372117% above its 10-year median of 0.06. GuruFocus rates NGM:COEGIN with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 930 Biotechnology companies, Coegin Pharma ranks worse than 91.18% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Coegin Pharma's share price is kr3.35.
Coegin Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.02. Hence, Coegin Pharma's PS Ratio for today is 223.33.
The historical rank and industry rank for Coegin Pharma's PS Ratio or its related term are showing as below:
NGM:COEGIN'
s PS Ratio Range Over the Past 10 Years
Min: 0.04 Med: 0.06 Max: 381
Current: 284.7
During the past 9 years, Coegin Pharma's highest PS Ratio was 381.00. The lowest was 0.04. And the median was 0.06.
NGM:COEGIN's PS Ratio is ranked worse than 91.18% of 930
companies
in the Biotechnology industry
Industry Median: 9.405
vs NGM:COEGIN: 284.70
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Coegin Pharma PS Ratio Related Terms
Coegin Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Coegin Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:COEGIN vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Coegin Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coegin Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coegin Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Coegin Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Coegin Pharma's Share Price of today is kr3.35. Coegin Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Coegin Pharma (NGM:COEGIN) has a PS Ratio of 223.33 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Coegin Pharma and its competitors. This is 372117% above median its historical median of 0.06. Over the past decade, Coegin Pharma's PS Ratio has ranged from 0.04 to 381.00. According to the industry distribution chart, Coegin Pharma ranks #848 out of 930 companies in the Biotechnology industry, placing it in the top 91.2%.
Is Coegin Pharma's PS Ratio too high?
Coegin Pharma's current PS Ratio of 223.33 is 372117% above median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 381.00. The Biotechnology industry median PS Ratio is 9.41. Coegin Pharma's value of 223.33 is 2274.6% above this industry median. Based on the distribution chart, Coegin Pharma ranks #848 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coegin Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coegin Pharma ranks #848 out of 930 companies for PS Ratio. This places Coegin Pharma in the lower half of its industry. The industry median PS Ratio is 9.41. Coegin Pharma's value of 223.33 is 2274.6% above this benchmark. Historically, Coegin Pharma's own PS Ratio has ranged from 0.04 to 381.00 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 9.41, Coegin Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coegin Pharma's current PS Ratio of 223.33 is 2274.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Coegin Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coegin Pharma's current PS Ratio is 223.33, which is 372117% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current PS Ratio of 223.33. The current PS Ratio is 223.33, which is 372117% above median its 10-year median of 0.06 and 2274.6% above the Biotechnology industry median of 9.41. Coegin Pharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current PS Ratio is 223.33 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
29GF Score
Get the complete analysis for NGM:COEGIN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
